Numinus Wellness (NUMI.T) research lab, Numinus Bioscience, received the nod from the Public Health Agency of Canada for their containment level 2 (CL2) pathogens and toxins license after the facility is upgraded.

This will result in the contribution of novel data on natural psychedelics, including additional intellectual property opportunities and another revenue avenue courtesy of research services extended to other companies.

“This biosecurity expansion will allow us to deeply understand not only the mechanisms behind Psilocybe mushrooms and other naturally occurring psychedelic materials but also their interaction with the human body. By performing testing and validation at a highly precise level, we will advance both our own IP development of finished products and scaled production processes, as well as contract services and sale of materials to research and industry partners,” said Sharan Sidhu, science officer and general manager for Numinus Biosciences.

This Public Health license adds to their existing Controlled Drugs and Substances Dealer’s License from Health Canada and contributes to accomplishing their long term strategies. These include establishing a natural psychedelic research center, lcense amendments and investment in equipment like Orbitrap, which identifies metabolites in the body.

The license gives Numinus the ability to start:

1)Study of pathogens and bacterial, fungal and microbial contaminants to identify baseline markers and optimal growth environments for Psilocybe mushrooms;

2)Bioassay studies using mammalian cell lines, to analyze the bioactivity of different whole mushroom formulations that contain both psilocybin and other psychedelic compounds;

3)Pharmacokinetic (PK) and pre-clinical studies using analysis of blood and other bodily fluids, to investigate reactions in the human body to whole mushrooms and other natural formulations.

—Joseph Morton